Mayo Clinic Proceedings

Cerhan, James R.
October 2006
Mayo Clinic Proceedings;Oct2006, Vol. 81 Issue 10, p1287
Academic Journal
The author reflects on the association of the oral contraceptive usage to breast cancer risks. The author emphasized the from the perspective of epidemiology and public health, the proper handling of the epidemiology of oral contraceptives use and health outcomes in both a beneficial and a deleterious manner should be followed. The identification of modifiable factors before first full-term pregnancy would support the window for breast cancer prevention to earlier in life.


Related Articles

  • ORAL CONTRACEPTIVES AND BREAST CANCER. Johnson, Kenneth H.; Millard, Peter S. // Journal of Family Practice;Oct1996, Vol. 43 Issue 4, p340 

    This article focuses on a study that was conducted to analyze the role of oral contraceptives as a risk factor of breast cancer. Since their introduction in the 1960's, the safety of oral contraceptives (OCs) has been widely debated. For example, OCs increase the risk of thromboembolism, but...

  • THE AUTHORS REPLY. Rosenberg, Lynn; Yuqing Zhang; Coogan, Patricia F.; Strom, Brian L.; Palmer, Julie R. // American Journal of Epidemiology;Sep2009, Vol. 170 Issue 6, p803 

    The article presents a response to a commentary on the paper "A Case-Control Study of Oral Contraceptive Use and Incident Breast Cancer." The use of less than 1 year of oral contraceptive use as the reference category in the analysis of the association between contraceptive use and breast cancer...

  • COMBINED ORAL CONTRACEPTIVES. Guillebaud, John // Pulse;3/8/2007, Vol. 67 Issue 9, p28 

    The article provides updates on the use of combined oral contraceptives (COC). A U.S. study of women aged 35-64 with breast cancer does not show an increased risk of the disease from COC use. Furthermore, levonorgestrel/norethisterone progestogens may reduce the risk of venous thromboembolism...

  • Oral Contraceptive Use and the Risk of Breast Cancer. Casey, Petra M.; Cerhan, James R.; Pruthi, Sandhya // Mayo Clinic Proceedings;Jan2008, Vol. 83 Issue 1, p86 

    The clinical impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more than a quarter of a million women are diagnosed as having breast cancer in the United States annually....

  • NEW CASE-HISTORY FACTS ON Birth-Control Pills. Spencer, Steven M. // Saturday Evening Post;6/30/1962, Vol. 235 Issue 26, p13 

    Comments on the prevalence of women who used oral contraceptives for family planning. Reaction of the Catholic Church officials against the use of oral pills for birth control; Assessment of the adverse effects of pills on the fertility of women; Classification of synthetic-hormone tablet as a...

  • Do Combined Oral Contraceptives Worsen Breastfeeding Outcomes? Jensen, Jeffrey T. // OB/GYN Clinical Alert;Feb2012, Vol. 29 Issue 2, p73 

    The article discusses a study conducted to compare effects of progestin-only and combined hormonal contraceptive pills on breastfeeding routine in postpartum women. It has been stated that the study focuses on two problems associated with healthy mothers that includes increasing rates of...

  • Factors determining use of oral contraceptive. Chudasama, Rajesh K.; Kavishwar, Abhay B.; Godara, Naresh R.; Moitra, Mohua // Internet Journal of Epidemiology;2009, Vol. 7 Issue 2, p1 

    To evaluate the factors determining use of oral contraceptives in reproductive age group women attending family planning clinic at New Civil Hospital, Surat, present study was conducted during October to December, 2007. After taking informed consent, 235 women were interviewed using pretested...

  • Ethinyl Estradiol/Levonorgestrel (Seasonale) for Oral Contraception. Wilson, Stephen A.; Kudis, Heather A. // American Family Physician;4/15/2005, Vol. 71 Issue 8, p1581 

    Ethinyl estradiol/levonorgestrel (Seasonale) is the first extended-cycle oral contraceptive. With Seasonale,women take active hormone for 84 consecutive days, then hormone-free tablets for 7 days, resulting in one menstrual period every three months. Each active tablet contains 30 mcg of ethinyl...

  • Brevinor.  // Royal Society of Medicine: Medicines;2002, p120 

    The article presents information on Brevinor, a proprietary, prescription-only compound preparation which can be used as a monophasic oral contraceptive of the COC standard strength type that combines an estrogen and a progestogen, in this case ethinylestradiol and norethisterone. It is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics